应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
MTVA MetaVia Inc
盘前交易 11-20 04:57:38 EST
1.07
+0.01
+0.94%
盘前
1.12
+0.05
+4.67%
04:44 EST
最高
1.15
最低
1.06
成交量
6.00万
今开
1.09
昨收
1.06
日振幅
8.49%
总市值
721.49万
流通市值
530.62万
总股本
674.29万
成交额
6.67万
换手率
1.21%
流通股本
495.91万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
MetaVia Inc宣布完成Da-1726治疗肥胖症1期第3部分研究的剂量滴定
美股速递 · 07-09
MetaVia Inc宣布完成Da-1726治疗肥胖症1期第3部分研究的剂量滴定
MetaVia股东批准反向股票分割,比例介于1比5至1比22之间
美股速递 · 06-09
MetaVia股东批准反向股票分割,比例介于1比5至1比22之间
MetaVia在EASL 2026大会上公布DA-1726更高剂量一期结果,支持其在肥胖与MASH领域的潜力
美股速递 · 05-27
MetaVia在EASL 2026大会上公布DA-1726更高剂量一期结果,支持其在肥胖与MASH领域的潜力
加载更多
公司概况
公司名称:
MetaVia Inc
所属市场:
NASDAQ
上市日期:
--
主营业务:
MetaVia Inc.于2014年10月根据特拉华州法律注册成立。该公司是一家临床阶段的生物技术公司,专注于开发用于治疗心血管代谢疾病的新型药物,其主要项目针对代谢功能障碍相关脂肪性肝炎和肥胖症。其研发管线包括GPR119激动剂vanoglipel和oxyntomodulin类似物双重激动剂DA-1726。
发行价格:
--
{"stockData":{"symbol":"MTVA","market":"US","secType":"STK","nameCN":"MetaVia Inc","latestPrice":1.07,"timestamp":1795122000000,"preClose":1.06,"halted":0,"volume":60027,"hourTrading":{"tag":"盘前","latestPrice":1.12,"preClose":1.07,"latestTime":"04:44 EST","volume":725,"amount":800.9668775000001,"timestamp":1795167856712,"change":0.05,"changeRate":0.046729,"amplitude":0.061963},"delay":0,"changeRate":0.009433962264150952,"floatShares":4959100,"shares":6742889,"eps":-3.176102,"marketStatus":"盘前交易","change":0.01,"latestTime":"11-20 04:57:38 EST","open":1.0923,"high":1.15,"low":1.06,"amount":66668.2552206,"amplitude":0.084906,"askPrice":1.27,"askSize":200,"bidPrice":0.9694,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-3.176102,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1795185000000},"marketStatusCode":1,"adr":0,"listingDate":1470369600000,"exchange":"NASDAQ","adjPreClose":1.07,"preHourTrading":{"tag":"盘前","latestPrice":1.12,"preClose":1.07,"latestTime":"04:44 EST","volume":725,"amount":800.9668775000001,"timestamp":1795167856712,"change":0.05,"changeRate":0.046729,"amplitude":0.061963},"postHourTrading":{"tag":"盘后","latestPrice":1.07,"preClose":1.07,"latestTime":"19:59 EST","volume":1453,"amount":1560.4923,"timestamp":1795136378155,"change":0,"changeRate":0,"amplitude":0.010093},"volumeRatio":0.8474474366375034},"requestUrl":"/m/hq/s/MTVA","defaultTab":"news","newsList":[{"id":"1125748257","title":"MetaVia Inc宣布完成Da-1726治疗肥胖症1期第3部分研究的剂量滴定","url":"https://stock-news.laohu8.com/highlight/detail?id=1125748257","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125748257?lang=zh_cn&edition=full","pubTime":"2026-07-09 20:31","pubTimestamp":1783600310,"startTime":"0","endTime":"0","summary":"MetaVia Inc宣布,其用于治疗肥胖症的药物Da-1726,在1期临床试验的第3部分研究中,已成功完成剂量滴定阶段。这一进展标志着该药物研发过程中的一个重要里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144525325","title":"MetaVia股东批准反向股票分割,比例介于1比5至1比22之间","url":"https://stock-news.laohu8.com/highlight/detail?id=1144525325","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144525325?lang=zh_cn&edition=full","pubTime":"2026-06-09 04:05","pubTimestamp":1780949115,"startTime":"0","endTime":"0","summary":"根据提交给美国证券交易委员会的文件,MetaVia Inc的股东已批准一项反向股票分割计划,具体执行比例将在1比5至1比22的范围内确定。\n该反向分割的最终比例将由公司董事会酌情决定,旨在提升每股股价,并可能满足相关证券交易所的持续上市要求。这一举措通常被股价长期低于规定门槛的公司所采用。\n股东授权董事会在此范围内实施反向分割,无需进一步征得股东同意。公司预计将在确定具体比例与生效日期后发布进一步公告。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171139494","title":"MetaVia在EASL 2026大会上公布DA-1726更高剂量一期结果,支持其在肥胖与MASH领域的潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=1171139494","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1171139494?lang=zh_cn&edition=full","pubTime":"2026-05-27 20:31","pubTimestamp":1779885096,"startTime":"0","endTime":"0","summary":"MetaVia公司在2026年欧洲肝脏研究学会(EASL)大会上,公布了其候选药物DA-1726更高剂量组的一期临床试验结果。新数据进一步支持了该药物在治疗肥胖及代谢相关脂肪性肝炎(MASH)方面的潜在应用价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.metaviatx.com","stockEarnings":[{"period":"1week","weight":-0.1769},{"period":"1month","weight":-0.1705},{"period":"3month","weight":-0.2671},{"period":"6month","weight":-0.7221},{"period":"1year","weight":-0.8727},{"period":"ytd","weight":-0.8729}],"compareEarnings":[{"period":"1week","weight":-0.0545},{"period":"1month","weight":-0.0692},{"period":"3month","weight":-0.0651},{"period":"6month","weight":-0.0399},{"period":"1year","weight":0.0803},{"period":"ytd","weight":0.0498}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"MetaVia Inc.于2014年10月根据特拉华州法律注册成立。该公司是一家临床阶段的生物技术公司,专注于开发用于治疗心血管代谢疾病的新型药物,其主要项目针对代谢功能障碍相关脂肪性肝炎和肥胖症。其研发管线包括GPR119激动剂vanoglipel和oxyntomodulin类似物双重激动剂DA-1726。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.000503},{"month":2,"riseRate":0.3,"avgChangeRate":0.007282},{"month":3,"riseRate":0.5,"avgChangeRate":-0.031121},{"month":4,"riseRate":0.4,"avgChangeRate":-0.109498},{"month":5,"riseRate":0.3,"avgChangeRate":-0.001142},{"month":6,"riseRate":0.5,"avgChangeRate":0.031858},{"month":7,"riseRate":0.2,"avgChangeRate":-0.02454},{"month":8,"riseRate":0.3,"avgChangeRate":-0.149871},{"month":9,"riseRate":0.363636,"avgChangeRate":0.051528},{"month":10,"riseRate":0.181818,"avgChangeRate":-0.195266},{"month":11,"riseRate":0.272727,"avgChangeRate":-0.106202},{"month":12,"riseRate":0.1,"avgChangeRate":-0.160075}],"exchange":"NASDAQ","name":"MetaVia Inc","nameEN":"MetaVia Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.54.0","shortVersion":"4.54.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"MetaVia Inc(MTVA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供MetaVia Inc(MTVA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"MetaVia Inc,MTVA,MetaVia Inc股票,MetaVia Inc股票老虎,MetaVia Inc股票老虎国际,MetaVia Inc行情,MetaVia Inc股票行情,MetaVia Inc股价,MetaVia Inc股市,MetaVia Inc股票价格,MetaVia Inc股票交易,MetaVia Inc股票购买,MetaVia Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"MetaVia Inc(MTVA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供MetaVia Inc(MTVA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}